✚ HEALTH & MEDICINE 5 YEARS HORIZON RESOLVES 14 NOV 2031 · in 5.0y

Clinical trials validate a predictive biomarker that detects Alzheimer's pathology at least 20 years before symptom onset.

The search queries the timeline of Alzheimer's pathogenesis. Resolution requires peer-reviewed validation and clinical adoption of a biomarker confirming disease progression decades before clinical symptoms.

Across 6 frontier models answering independently, the panel thinks this is unlikely: the median is 22%.

They do not agree: Grok puts it at 72% and Claude at 4%, 68 points apart. A spread that wide usually means the question turns on something none of them can see yet.

Nothing is settled until 14 Nov 2031, when the outcome is checked against sources and every number above gets a permanent score.

MODEL BY MODEL

What each one said

  • GrokxAI

    Plasma p-tau and amyloid assays already track 15–25y preclinical change; 5y more trials will lock 20y prediction.

    • DIAN, A4 and TRAILBLAZER already show CSF/plasma p-tau217 and amyloid PET rise ~20y before CDR 0.5; confirmatory RCTs finish 2027-30.
    • FDA cleared CSF and plasma tests 2022-25; CLIA labs and CMS coverage follow within 18 months of a positive trial readout.
    • Only a failed replication in late-onset sporadic cohorts or regulatory demand for 25y data would drop this below 50.
    x-ai/grok-4.6 · asked 15 Nov 2026
    72%
  • GPTOpenAI

    The key hinge is whether long-running asymptomatic cohorts establish a biomarker-to-progression link strong enough for clinical use.

    • Amyloid PET and plasma p-tau already become abnormal roughly 15–20+ years before dementia in familial and cohort studies.
    • By 2031, trial sponsors, journals, regulators, and guidelines must converge on predictive validation rather than mere early detection.
    • My view rises sharply if prevention trials show biomarker-positive, symptom-free people have reliably altered later clinical trajectories.
    openai/gpt-5.6-terra · asked 15 Nov 2026
    57%
  • GeminiGoogle

    Proving a 20-year lead time requires long longitudinal cohort follow-ups that cannot easily conclude within five years.

    • DIAN and ADNI cohorts already track pre-symptomatic shifts up to 20 years, but validating predictive thresholds takes decades.
    • FDA requires prospective validation linking early markers like p-tau217 to guaranteed progression, which faces huge survival bias.
    • Approval of blood-based p-tau tests for early risk is surging, but formal trial validation of a 20-year window by 2031 is too tight.
    google/gemini-3.8-flash · asked 15 Nov 2026
    22%
  • DeepSeekDeepSeek

    Whether a validated biomarker can predict Alzheimer's pathology 20+ years before symptoms, not just 10-15.

    • CSF p-tau217 and plasma p-tau217 assays already detect amyloid pathology 10-15 years pre-symptom; the 20-year threshold is the binding constraint.
    • Validation requires longitudinal cohorts with 20+ year follow-up, and the best existing datasets (BioFINDER, ADNI) began around 2004-2005, so 20-year data matures only…
    • Clinical adoption lags validation by 3-5 years; FDA cleared Lumipulse plasma p-tau217 in 2022 for amyloid, but a 20-year predictive claim needs prospective…
    deepseek/deepseek-v4.1-flash · asked 15 Nov 2026
    22%
  • QwenAlibaba

    Requires prospective trial validation at the extreme tail of the preclinical window plus clinical adoption—both are multi-year processes.

    • DIAN has ~20 years of longitudinal data by 2031, but that covers only autosomal dominant AD (~1% of cases); sporadic AD cohorts lack the follow-up depth to confirm a…
    • Even if DIAN-TU prevention trial results show biomarker signal at 20+ years, regulatory approval and clinical adoption typically adds 3–5 years beyond pivotal data.
    • A development that would raise this: FDA granting breakthrough designation to a blood-based p-tau assay specifically for pre-symptomatic screening in high-risk…
    qwen/qwen3.8-max-0902 · asked 15 Nov 2026
    6%
  • ClaudeAnthropic

    Full clinical validation and adoption of a 20-year-early biomarker by 2031 is far beyond current research maturity.

    • Current amyloid/tau biomarkers detect pathology roughly 10-15 years pre-symptom at best, not validated 20-year windows.
    • Clinical adoption requires decades-long longitudinal cohort data that simply can't mature by 2031 given current study start dates.
    • A breakthrough in a tractable new biomarker (blood-based tau variants) with retrospective cohort validation could change this but adoption lag remains the bottleneck.
    anthropic/claude-sonnet-5 · asked 15 Nov 2026
    4%

6 of 6 models answered · 68 points between the highest and lowest. None was shown the market price.

WHAT DO YOU THINK?
loading…

Question sourced from a news sweep on 15 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.